Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 16

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 16
---
 or non-competitive before we recover the expense
of developing and commercializing our drug candidates. Such competitors could also recruit our employees, which could negatively impact
our level of expertise and our ability to execute our business plan.

If healthcare insurers and other organizations do not pay for
our drug candidates or impose limits on reimbursement, our future business may suffer.

Our drug candidates may be
rejected by the market due to many factors, including cost. The continuing efforts of governments, insurance companies and other payers
of healthcare costs to contain or reduce healthcare costs may affect our future revenues and profitability. In Australia and certain foreign
markets, the pricing of pharmaceutical products is subject to government control. We expect initiatives for similar government control
to continue in the United States and elsewhere. The adoption of any such legislative or regulatory proposals could harm our business and
prospects.

Successful commercialization
of our drug candidates will depend in part on the extent to which reimbursement for the cost of our products and related treatment will
be available from government health administration authorities, private health insurers and other organizations. Our drug candidates may
not be considered cost-effective and reimbursement may not be available to consumers or may not be sufficient to allow our products to
be marketed on a competitive basis. Third-party payers are increasingly challenging the price of medical products and treatment. If third
party coverage is not available for our drug candidates, then the market acceptance of these drug candidates will be reduced. Cost-control
initiatives could decrease the price we might establish for drug candidates, which could result in product revenues lower than anticipated.
If the price for our drug candidates decreases, or if governmental and other third-party payers do not provide adequate coverage and reimbursement
levels, our potential revenue and prospects for profitability will suffer.

We could become exposed to product liability claims that could
harm our business.

The testing, marketing and
sale of therapeutic products entails an inherent risk of product liability. We rely on a number of third-party researchers and contractors
to produce, collect, and analyze data regarding the safety and efficacy of our drug candidates. We also have quality control and quality
assurance in place to mitigate these risks, as well as professional liability and clinical trial insurance to cover financial damages
in the event that human testing is done incorrectly or the data is analyzed incorrectly.

Notwithstanding our control
procedures, we may face product liability exposure related to the testing of our drug candidates in human clinical trials. If any of our
drug candidates are approved for sale, we may face